



Editorial

The silent partner in the lab – How artificial intelligence is redefining molecular biochemistry

Sandeep Singh^{1*}, Umesh Kumar¹, Jaspreet Singh¹

¹Dept. of Biochemistry, Pt. B.D. Sharma Post Graduate Institute of Medical, Rohtak, Haryana, India.

Received: 15-08-2025; Accepted: 09-10-2025; Available Online: 24-10-2025

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

The landscape of clinical biochemistry is undergoing a transformation as profound as the advent of PCR or next-generation sequencing. This transformation is not driven by a new instrument, but by an intangible yet powerful force: Artificial Intelligence (A.I.). As we stand at this inflection point, it is imperative to explore and embrace the burgeoning role of A.I. as the indispensable partner in advancing molecular techniques, a theme central to the scope of the International Journal of Clinical Biochemistry and Research (IJCBR). For decades, progress in molecular biology was a function of meticulous manual experimentation. Today, A.I. and machine learning (ML) algorithms are infusing these techniques with unprecedented speed, accuracy, and predictive power, moving us from mere observation to intelligent analysis and discovery.¹

1. Revolutionizing Core Techniques

1. **In genomics and disease prediction:** A.I. is no longer just aligning sequences. It can now predict the functional impact of non-coding genetic variants, identify complex multi-gene interaction networks underlying polygenic diseases, and even deconvolute the intricate relationships in transcriptomic data.² This moves us beyond simple association towards true mechanistic understanding and personalized risk assessment.
2. **In proteomics and metabolomics:** The vast, high-dimensional data generated by mass spectrometry and NMR is a perfect substrate for A.I. Machine learning models can identify novel protein biomarkers from complex biofluids, distinguish disease subtypes with

unparalleled precision based on metabolic fingerprints, and map entire signaling pathways, accelerating drug target discovery.

3. **In structural biology:** The landmark achievement of AlphaFold2 in predicting protein 3D structures with high accuracy has democratized structural biology. This A.I.-driven capability is accelerating research in drug design, enzyme engineering, and understanding the molecular basis of genetic disorders, tasks that were previously time and resource-intensive.
4. **In diagnostic imaging and cytology:** At the intersection of molecular biology and pathology, A.I. algorithms are now capable of analyzing histopathological slides and cellular images to detect subtle, pre-malignant changes or specific molecular alterations directly from tissue morphology, a field known as 'computational pathology'.³

Aligning with the IJCBR Mission: Transforming Publication and Country.

This paradigm shift aligns perfectly with our journal's motto: Transforming quality publication and transforming country.

2. Transforming Quality Publication

The integration of A.I. necessitates a new standard for methodological reporting. IJCBR commits to leading this change by encouraging submissions that not only utilize A.I. but also detail the models, data curation processes, and validation metrics with rigor and transparency. We aim to be a forum for discussing the ethical use of A.I., ensuring the

*Corresponding author: Sandeep Singh
Email: sandeephere18@gmail.com

research we publish is not only innovative but also reproducible and trustworthy.⁴

3. Transforming Country

The adoption of A.I. in biomedical research is a great equalizer. For a transforming nation, investing in A.I.-driven biochemistry is a strategic imperative. It allows for the development of cost-effective, locally relevant diagnostic tools, the creation of population-specific genomic databases, and the fostering of a homegrown biotechnology sector poised for the future. By publishing research in this domain, IJCBBR aims to catalyze this national transformation, encouraging our scientific community to leverage A.I. to solve local health challenges and compete on a global stage.

4. The Road Ahead

The fusion of A.I. and molecular biochemistry is not without challenges—data quality, algorithmic bias, and the need for interdisciplinary training are significant hurdles. However, the potential is limitless. A.I. is evolving from a data analysis tool to an active partner in hypothesis generation and experimental design.

This issue of IJCBBR is a call to the global biochemistry community. We invite you to share your research, reviews, and perspectives on how A.I. is reshaping your work. Let us collaborate to harness this powerful synergy, guiding its development to ensure it serves the ultimate goal of all biochemical research: to unravel the mysteries of life and alleviate human suffering.

5. Source of Funding

None.

6. Conflict of Interest

None.

References

1. Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. *Nat Rev Gen.* 2015;16(6):321–32. <https://doi.org/10.1038/nrg3920>.
2. Liebal UW, Phan ANT, Sudhakar M, Raman K, Blank LM. Machine Learning Applications for Mass Spectrometry-Based Metabolomics. *Metabolites*, 2020;10(6):243. <https://doi.org/10.3390/metabo10060243>.
3. Jumper J, Evans R, Pritzel A. Highly accurate protein structure prediction with Alpha Fold. *Nat.* 2021;596(7873):583–9. <https://doi.org/10.1038/s41586-021-03819-2>.
4. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology. *Nat Rev Clin Oncol.* 2019;16(11):703–15. <https://doi.org/10.1038/s41571-019-0252-y>.

Cite this article: Singh S, Kumar U, Sing J. The silent partner in the lab – How artificial intelligence is redefining molecular biochemistry. *Int J Clin Biochem Res.* 2025;12(3):132-133.